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Summary
A hallmark of obesity is chronic low-grade inflammation, which plays a major role
in the process of atherosclerotic cardiovascular disease (ACVD). Gut microbiota is
one of the factors influencing systemic immune responses, and profound changes
have been found in its composition and metabolic function in individuals with obe-
sity. This systematic review assesses the association between the gut microbiota and
markers of low-grade inflammation in humans. We identified 14 studies which
were mostly observational and relatively small (n = 10 to 471). The way in which
the microbiome is analysed differed extensively between these studies. Lower gut
microbial diversity was associated with higher white blood cell counts and high
sensitivity C-reactive protein (hsCRP) levels. The abundance of Bifidobacterium,
Faecalibacterium, Ruminococcus and Prevotella were inversely related to different
markers of low-grade inflammation such as hsCRP and interleukin (IL)-6. In addi-
tion, this review speculates on possible mechanisms through which the gut microbi-
ota can affect low-grade inflammation and thereby ACVD. We discuss the
associations between the microbiome and the inflammasome, the innate immune
system, bile acids, gut permeability, the endocannabinoid system and TMAO.
These data reinforce the importance of human research into the gut microbiota
as potential diagnostic and therapeutic strategy to prevent ACVD.
Keywords: Atherosclerotic cardiovascular disease, gut microbiome, inflammation,
obesity.
Abbreviations: ACVD, atherosclerotic cardiovascular disease; hsCRP, high
sensitivity C-reactive protein; IL, interleukin; TNF-α, tumour necrosis factor alpha;
PRRs, pattern recognition receptors; LPS, lipopolysaccharide; LGC, low gene count;
L. reuteri, Lactobacillus reuteri; qPCR, quantitative polymerase chain reaction;
F. prausnitzii, Faecalibacterium prausnitzii; E. coli, Escherichia coli; C. nexile,
Clostridium nexile; B. fragilis, Bacteroides fragilis; Staph.aureus, Staphylococcus
aureus; IFN-γ, interferon gamma; A. muciniphila, Akkermansia muciniphila;
R. gnavus, Ruminococcus gnavus; P. nigrescens, Prevotella nigrescens; BMI, body
mass index; PAMPs, pathogen-associated molecular patterns; TLR, toll-like recep-
tor; NOD, nucleotide-binding oligomerization domain; HFD, high fat diet; SCFAs,
short chain fatty acids; Treg, regulatory T cells; GPR, G protein coupled receptors;
GLP-2, glucagon-like peptide 2; eCB system, endocannabinoid system; NLRP6,
NOD-like receptor family pyrin domain containing 6; TGF-β, transforming growth
factor beta; TMAO, trimethylamine-N-oxide.
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Introduction
The worldwide pandemic of obesity has led to an increased
prevalence of cardiovascular risk factors (diabetes mellitus,
hypertension and dyslipoproteinemia) and atherosclerotic
cardiovascular disease (ACVD). This complex of cardiovas-
cular risk factors is labelled ‘the metabolic syndrome’,
which is associated with a twofold higher risk for ACVD
(1). Losing weight is notoriously difficult and most often
only temporary. Interestingly however, not all individuals
with obesity develop the metabolic syndrome and resulting
ACVD. Approximately 20–30% of the individuals with
obesity are metabolically healthy, and their risk for ACVD
is substantially lower than in individuals with metabolically
unhealthy obesity (2,3). A better understanding of metabol-
ically healthy obesity might offer novel treatment strategies
to prevent ACVD in patients that are overweight (4). Indi-
viduals with obesity that develop ACVD are often charac-
terized by a chronic low-grade inflammatory status,
described as ‘meta-inflammation’ (5,6). It has been hypoth-
esized that differences in inflammatory status partly explain
the individual differences in cardiovascular risk.
Since the discovery that tumour necrosis factor (TNF)-α is
overexpressed in the adipose tissue of mice with obesity, nu-
merous studies have focused on the role of adipose tissue in
the development of inflammation (7). The current hypothe-
sis states that fat mass expands due to a positive energy bal-
ance, which leads to a pro-inflammatory reaction of both
adipocytes and surrounding immune cells. While initially
considered to be of little relevance for metabolic dysregula-
tion and cardiovascular risk in obesity-related disease, the
modest increases in circulating inflammatory mediators
have in recent years been found to be strongly associated
with the development of non-alcoholic fatty liver disease,
type 2 diabetes and atherosclerosis (8,9). These pro-
inflammatory pathways are partly mediated via pattern
recognition receptors (PRRs). The beneficial effects of
blocking inflammatory pathways on ACVD were recently
underscored by the results of the CANTOS trial.
Canakinumab, a human monoclonal antibody that inhibits
the pro-inflammatory cytokine interleukin (IL)-1β reduced
cardiovascular death, non-fatal myocardial infarction and
non-fatal stroke (10). Despite this progress, the initial trig-
gers of inflammation in patients with metabolic dysregula-
tion remain obscure.
Several studies suggest that the obesity-related systemic
inflammation is at least partly driven by an altered gut
microbial composition and function (11). The human gut
microbiota consists of approximately 10^13–10^14 mi-
crobes, including bacteria, viruses, fungi and protozoa.
Besides their function in intestinal epithelial homeostasis,
development of the immune system, protection against
pathogens and energy homeostasis (12–15), the gut
microbiota also plays a role in pathophysiological mecha-
nisms associated with different diseases (16).
Profound changes have been observed in the composition
and metabolic function of gut microbiota in individuals
with obesity. Obesity was first reported to be associated
with a change of gut microbiota by Ley et al. in 2005;
characterized by obesity, ob/ob mice appeared to have less
phylum Bacteroidetes and more Firmicutes compared with
lean phenotypes (17). A further major observation came
from Turnbaugh et al. who reported that the core gut
microbiome of individuals affected by obesity has an in-
creased capacity for energy harvesting (18).
To explore whether the gut microbiota contributes to
chronic inflammation as driver for ACVD in humans, we
conducted a systematic review of studies investigating the
role of the gut microbiome in chronic low-grade inflamma-
tion. In this review, we also discuss possible mechanisms by
which the gut microbiota can influence chronic low-grade
inflammation and thereby contribute to the development
and progression of ACVD.
Methods
Identification and selection of articles
A systematic review of peer-reviewed studies examining the
role of the gut microbiome on chronic low-grade inflamma-
tory markers in human populations was undertaken. A pro-
tocol was developed a priori, outlining the review aim and
procedure. The literature search was conducted using
Medline (Pubmed), CINAHL and the Cochrane Library
from inception until November 2017. Key MeSH subject
terms and keywords pertaining to the gut microbiome and
inflammation in correlation to obesity or ACVD were in-
cluded. The following search string was employed: ((‘Gas-
trointestinal Microbiome’) OR (‘Gut microbiome’)) AND
((‘Inflammation’) OR (‘Inflammation Mediators’) OR
(‘Host-Pathogen Interactions’) OR (‘Immune System’) OR
(‘Immunity’) OR (‘Adaptive Immunity’)) AND ((‘Obesity’)
OR (‘Overweight’) OR (‘Cardiovascular Diseases’)
OR (‘Coronary Disease’) OR (‘Atherosclerosis’)) Filters:
Humans.
Two reviewers (I.v.d.M. and J.R.) independently evaluated
eligibility of studies based on the title and abstract using the
following inclusion criteria: (i) participants older than
18 years of age; (ii) investigation of the gut microbiome;
(iii) investigation of a quantitative measure of inflammation,
e.g. inflammatory cell count, hsCRP, cytokines or a potential
trigger for inflammation like circulating lipopolysaccharide
(LPS); and (iv) full text availability in the English language.
The presence of infectious or inflammatory diseases (i.e. in-
flammatory bowel disease, HIV and rheumatoid arthritis)
in the study population was the only exclusion criterion.
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Afterwards, full-text articles were assessed independently
by two reviewers (I.v.d.M. and J.R.).We also checked
for cited articles in original research articles and reviews
that addressed the mechanistic links between the gut
microbiome and low-grade inflammation.
Study quality assessment
The included observational studies were assessed on their
quality using an adapted scale from the Newcastle–Ottawa
scale for quality assessment of cohort and case–control
studies (NOS scale). This scale is a modified version of the
NOS scale, as also used by several other studies (19,20).
For the included non-randomized intervention studies, we
used the conventional NOS scale. A study with a NOS score
of 7 or more can be considered to be a study of ‘good’
quality (21). For the randomized intervention studies, we
used the Cochrane risk of bias 2.0 (22).
Results
Data extraction and quality assessment
The search process identified 629 articles for potential inclu-
sion. In total, 260 manuscript contained original research
data. After reviewing the titles and abstracts, 61 studies
met the initial inclusion criteria (Fig. 1). Following the initial
selection, another 51 studies were excluded, mainly because
they were not original studies or the study did not investi-
gate the direct relation between the gut microbiome and in-
flammatory markers at baseline, leading to inclusion of 10
studies. We also checked the reference list of the 61 non-
Figure 1 PRISMA flow diagram with schematic presentation of the study assessment and exclusion stages. [Colour figure can be viewed at
wileyonlinelibrary.com]
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review studies that initially met the inclusion criteria. Addi-
tionally, we checked 369 reviews, of which 49 were of inter-
est and of which we checked the reference list. In total, 34
original manuscripts met the inclusion criteria. However,
the majority of these studies were excluded, because they
did not report on microbiome analysis or used a surrogate
marker to assess the gut microbiome. An additional five ar-
ticles were identified via these reference lists for cited arti-
cles. We identified one study that presented a data set that
was published more than once (trial registered as
ISRCTN88720134). For this data set, we selected the study
reporting on the largest cohort (23). Two other studies used
the same data set; however, they performed different
analyses (24,25). Therefore, both studies were included. Fi-
nally, this resulted in 14 unique manuscripts. The 14 articles
included 21 populations with a total of 1,418 individuals
(see Tables 1 and S1 for detailed information of each study).
For the intervention studies, we only included the data at
baseline in order to overcome the effect of the intervention
on the relation between the gut microbiome and
inflammation.
Eight out of the 11 observational and non-randomized
studies were considered to be studies of good quality based
on the NOS score (Tables S2 and S3). The methodological
quality of the randomized intervention studies ranged from
low risk to high risk for bias (three studies; Table S4).
Table 1 Detailed information of all studies included in this systematic review
Study – year Ref Country Population Mean
age
Mean
BMI
Study design Statistical analyses Method
microbiome
analysis
Schirmer et al. –
2016
27 The
Netherlands
471 healthy subjects 29 ± 14 23 ± 3 Observational Spearman correlation with
Benjamini–Hochberg
correction
Quantitative
metagenomics
Dao MC et al. –
2016
24 France 49 subjects with
overweight
42 ± 12 33 ± 1 Dietary intervention Kruskal–Wallis test with
Bonferroni correction
Quantitative
metagenomics
Radilla-VÃ¡zquez
RB et al. – 2016
35 Mexico 32 subjects with
obesity and 32
control subjects
21 ± 2
and
21 ± 2
21 and
35
Observational Kruskal–Wallis test qPCR
Rajkumar H
et al. – 2014
33 India 60 subjects with
overweight
49 29 Randomized
controlled trial with
probiotic
ANOVA Culturing
Le Chatelier E
et al. – 2013
26 Denmark 169 subjects with
obesity and 123
control subjects
57 30 Observational Linear model adjusting for
age and sex; Benjamini–
Hochberg method
Quantitative
metagenomics
Cotillard A
et al. – 2013
25 France 38 subjects with
obesity and 11
subjects with
overweight
44 ± 2
and
46 ± 3
49 ± 1
and
28 ± 1
Dietary intervention Mann–Whitney test Quantitative
metagenomics
Clemente-Postigo
M et al. – 2013
23 Spain 10 subjects 48 ± 2 28 ± 3 Randomized cross-
over trial with
alcohol intervention
Pearson’s correlation test qPCR
Martínez I
et al. – 2013
31 USA 28 healthy subjects 26 ± 6 25 ± 5 Randomized cross-
over trial with
dietary intervention
Pearson’s correlation test 16S rRNA
gene analysis
Claesson MJ
et al. – 2012
30 Ireland 165 older and 13
young subjects
78 ± 8
and
36 ± 6
27 ± 5
and?
Observational Linear quantile regression 16S rRNA
gene analysis
Brignardello J
et al. – 2010
52 Chile 6 subjects with
obesity and 6 control
subjects
34 ± 12
and
30 ± 8
36 ± 5
and
24 ± 2
Observational Spearman rank test G + C peak
content
analysis
Mikelsaar M
et al. – 2010
28 Estonia 38 older subjects 72 ± 5 27 ± 4 observational Linear multiple regression
analysis adjusted for age,
sex and BMI
qPCR
Furet JP
et al. – 2010
32 France 30 subjects with
obesity and 13
control subjects
44 ± 2
and
36 ± 3
48 ± 2
and
22 ± 0
Bariatric surgery
intervention
Principal component
analysis combined with
Spearman analysis
qPCR
Biagi E
et al. – 2010
34 Italy 84 subjects 25–104 Observational Pearson’s correlation test Microarray
analysis,
qPCR
Tiihonen K
et al. – 2010
29 Finland 20 subjects with
obesity and 20
control subjects
33 ± 2
and
23 ± 2
33 ± 2
and
23 ± 2
Observational Pearson’s correlation test qPCR
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Circulating immune cell counts
Three studies investigated circulating immune cell counts as
marker of inflammation. The details of these studies and the
results are summarized in Table 2a. A low gene count (LGC)
of the gut microbiome correlated with a higher white blood
cell count in a large Danish population-based study
employing metagenomics analysis (26). Another large
Dutch cohort study that included mainly healthy younger
individuals did not find a relationship between the gut
microbiome composition and white blood cell count (27).
In a small study in elderly, a higher white blood cell count
correlated with the presence of the species Lactobacillus
reuteri (L. reuteri) as analysed by quantitative polymerase
chain reaction (qPCR) (28).
C-reactive protein
The majority of studies investigating the relation between
the gut microbiome and low-grade inflammation used (hs)
CRP as marker. In Table 2b, we provide an overview of
the details and results of these studies. An LGC phenotype
was associated with increased hsCRP levels in the aforemen-
tioned Danish population-based study (26) and revealed a
tendency towards an increased hsCRP in another smaller
diet intervention study (25). The total bacterial cell counts
related inversely with hsCRP in another study (29). Six
studies examined the relationship between the phylum or
species abundance with (hs) CRP levels. The largest study
included 165 older individuals and specifically measured
16S rRNA by massive parallel sequencing finding that
lower levels of the Oscillibacter co-abundance group and
higher levels of the Bacteroides co-abundance group
coincided with increased levels of CRP (30). Two other
small studies reported that lower levels of the genera
Faecalibacterium and Ruminococcus, and Faecalibacterium
prausnitzii (F. prausnitzii) species correlated with increased
hsCRP levels (31,32). These studies were fairly similar in
both samples sizes and methods of microbiome analysis.
The first study was a randomized cross-over trial with
4-week diet intervention that included 28 young adults
and used 16S rRNA gene sequencing to reconstruct
microbiome taxonomic composition (31). The second study
was an intervention study with bariatric surgery in 30 indi-
viduals with obesity. They analysed the gut microbiota by
16S rRNA gene sequencing combined with qPCR analysis
(32). For the current review, we only considered the
correlation results at baseline from both studies. Next to
that, the study by Rajkumar et al. who found that lower
levels of the genera Lactobacillus, Bifidobacterium and
Streptococcus and higher levels of the species Escherichia
coli (E. coli) correlated with increased (hs) CRP in 60
healthy adults affected by overweight (33), used
bacterial culturing methods to identify bacteria. Plates
were incubated in triplicate using selective media for
enumeration of total aerobes, anaerobes, coliforms, E.
coli, Bifidobacterium, Lactobacillus and Streptococcus
thermophilus.
Cytokines
Six studies investigated relationships between the abun-
dance of gut microbiome species and pro-inflammatory cy-
tokines. The details and results of these studies are
summarized in Table 2c. The total bacterial cell count was
positively related to circulating TNF-α levels in a small
Finnish cohort study using qPCR as microbiota analysis
method (29). The largest study on the relationship between
specific genera, species and cytokines was mentioned before
and included 165 older individuals (30). Lower levels of the
Ruminoccocus and Prevotella co-abundance group, as well
as higher levels of theOscillibacter co-abundance group, co-
incided with higher IL-6 levels. Two small studies men-
tioned in the hsCRP section also reported a negative
correlation between the family Ruminococcaceae (31) and
species F. prausnitzii (32) with IL-6 levels. The Italian study
that included four different age groups, ranging between 25
and 104 years of age (35), showed a negative correlation be-
tween IL-6 and species Eubacterium hallii, Eubacterium
ventriosum, Eubacterium rectale, Clostridium nexile (C.
nexile) and species in the Clostridium cluster XIVa. A posi-
tive correlation with circulating IL-6 was observed for the
genera Haemophilus, Pseudomonas, Serratia, Yersinia, Vib-
rio and Bacillus, and species Eggherthella lenta, Eubacte-
rium cylindroides, E.coli and Klebsiella pneumoniae.
Increased levels of the genera Leminorella, Proteus and
Bacillus, and species Alcaligenes faecalis, Eggerthella lenta
and Eubacterium cylindroides correlated with higher levels
of IL-8, while decreased levels of the species Eubacterium
halli, Eubacterium ventriosum, Eubacterium rectale, C.
nexile and species within the Clostridium cluster XIVa re-
lated to higher IL-8 levels; this study investigated the gut
microbiome by microarray and qPCR analysis (35).
Among all microbiome–IL association studies, Schirmer
et al. included the largest number of individuals, n = 471,
all healthy and mainly young. They investigated cytokine re-
sponses ex vivo in peripheral blood mononuclear cells
(PBMCs) and whole blood stimulated with five different mi-
crobial pathogens in relation to microbial taxonomy and
functionality, as analysed by metagenomics (27). For the
purpose of this review, we have focused on the bacterial
taxa and bacteria-derived stimulations: E. coli-derived
LPS, Bacteroides (B.) fragilis representing gram-negative
bacteria and Staphylococcus (Staph.) aureus representing
gram-positive bacteria. For these stimulations, three
monocyte-derived cytokines (IL-1β, IL-6 and TNF-α) and
three lymphocyte-derived cytokines (interferon [IFN]-γ,
IL-17 and IL-22) were measured. No association was found
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Table 2 Summary of findings of included studies in this systematic review per marker of inflammation
Table 2a Gut microbiome measurements in relation to white blood cell counts
Study Summary of finding
Le Chatelier et al. (26) The phenotype of low gene count people was associated with a more marked inflammatory phenotype with higher white blood
cell counts, model adjusted for age and sex (q = 0.014; P = 0.002).
Schirmer et al. (27) No effect of microbial composition on the most important immune cell population (T/B lymphocytes, monocytes, neutrophils,
NK cells) was detected.
Mikelsaar M et al. (28) The higher white blood cells count was positively related (r = 0.434, P = 0.007) to the presence of L. reuteri, also after
adjustment for age, sex and BMI (adj. R2 = 0.193, P = 0.027).
Table 2b Gut microbiome measurements in relation to (hs)CRP
Study Summary of finding
Le Chatelier E et al. (26) The phenotype of low gene count people was associated with a more marked inflammatory phenotype with increased hsCRP
(q = 0.012; P < 0.001).
Cotillard A et al. (25) The low gene count group had a trend towards higher inflammation (hsCRP).
Tiihonen K et al. (29) An inverse correlation between the total faecal microbial counts and serum hsCRP (r = 0.51, P = 0.04) was found.
Dao MC et al. (24) No difference in hsCRP between high and low Akkermansia group
Claesson MJ et al. (30) A reduction in the Oscillibacter co-abundance group and increase in the Bacteroides co-abundance group, coincided with
increased levels of CRP.
Martínez I et al. (31) Negative correlation between the family Ruminococcaceae (r = 0.59, P = 0.0024) with hsCRP were revealed. Within this
family, the genera Faecalibacterium and Ruminococcus displayed negative correlations with hsCRP (r = 0.48, P < 0.05 and
r = 0.60, P < 0.01, respectively).
Furet JP et al. (32) The strongest associations were found for the amount of the species F. prausnitzii, which was negatively correlated with serum
concentrations of inflammatory circulating markers, hsCRP (Rs 0.54, P < 0.01)
Rajkumar H et al. (33) Subjects with more than 3 mg L1 hsCRP has significantly lower Lactobacilli, Bifidobacteria, and Streptococcus and higher E.
coli when compared with those who had less than 3 mg L
1
.
Brignardello J et al. (34) The G + C peak values correlated negatively with the higher CRP levels (r = 0.68; P < 0.02).
Table 2c Gut microbiome measurements in relation to cytokines
Study Summary of finding
Schirmer et al. (27) At genus level: A negative relation was present between Roseburia and IL-6 levels (after B. fragilis stimulation).
A negative relation was present between Faecalibacterium, Atopobium and IL-17 levels (after Staph. aureus stimulation).
A positive relation was present between Escherichia, Anaerotruncus, Coprobacillus, Clostridium and Anaerostipes and IL-17
levels (after Staph. aureus stimulation).
A negative relation was present between Oscillibacter (after LPS stimulation), Barnesilla (after LPS and B. fragilis stimulation),
Leuconostoc (after B. fragilis stimulation) and IFN-γ levels.
A positive relation was present between Megasphaera (after B. fragilis stimulation) and IFN-γ levels.
A negative relation was present between Bilophila, Odoribacter and TNF-α levels (after LPS stimulation).
A positive relation was present between Methanosphaera and TNF-α levels (after LPS stimulation).
At species level: A negative relation was present between Lachnospiraceae bacterium 5 1 65FAA and IL-6 levels (after Staph.
aureus stimulation).
A negative relation was present between Parabacteroides johnsonii and IL-17 levels (after Staph. aureus stimulation).
A positive relation was present between Escherichia spp, B. intestinalis, Anaerotruncus spp and IL-17 levels (after Staph.
aureus stimulation).
A negative relation was present between B. eggerthii, Coprococcus comes and IL-22 levels (after Staph. aureus stimulation).
A positive relation was present between B. cellulosilyticus and R. gnavus (both after Staph. aureus stimulation), Megasphaera
sp., Eubacterium limosum, B. nordii (all after B. fragilis stimulation) and IFN-γ levels.
A negative relation was present between Lachnospiraceae bacterium 9 1 57FAA and IFN-γ levels (after Staph. aureus
stimulation).
A negative relation was present between Clostridium leptum, Alistipes finegoldii, Bilophila spp, Bilophila wadsworthia, Alistipes
onderdonkii, Enterococcus faecium, Collinsella intestinalis, Odoribacter splanchnicus and TNF-α levels (after LPS stimulation).
A positive relation was present between Acidaminococcus intestini, Methanospaera stadtmanae, L. acidophilus and TNF-α
(after LPS stimulation)
Claesson MJ et al. (30) A reduction in abundance of Ruminococcus and Prevotella and increased abundance of Oscillibacter co-abundance groups
was accompanied by an increase in IL-6 levels.
Martínez I et al. (31) A negative correlation between the family Ruminococcaceae and IL-6 was revealed (P < 0.05).
Biagi E et al. (35) IL-8 correlated positively with Alcaligenes faecalis et rel, Leminorella, and Proteus et rel, Bacillus, Egghertella lenta et rel and
Eubacterium cylindroides et rel.
IL-6 correlated positively with E. coli et rel, Haemoplihus, Klebsiella pneumoniae et rel, Pseudomonas, Serratia, Yersinia et rel
and Vibrio, Bacillus, Egghertella lenta et rel and Eubacterium cylindroides et rel.
Eubacterium halli, Eubacterium ventriosum, Eubacterium rectale, C. nexile and Clostridium cluster XIVa were inversely
correlated with IL-6 and IL-8.
Tiihonen K et al. (29) Serum TNF-α was associated with the total number of bacteria (r = 0.42, P = 0.006).
(Continues)
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between bacteria-derived stimulations and IL-1β. On the
other hand, IL-6 production after Staph. aureus stimulation
was negatively related to the species Lachnospiraceae bacte-
rium 5 1 65FAA. After stimulating PBMCs with LPS, TNF-α
production was negatively related with Alistipes spp, Clos-
tridium spp and Bilophila spp among others. For IL-17, 5
positive associations with genera were identified, including
genus Clostridium, as well as two negative correlations,
with Faecalibacterium and Atopobium. A differential IFN-
γ response was observed for all bacterial stimulations.
Circulating lipopolysaccharide
Three studies investigated the relationship between the gut
microbiome and circulating LPS levels. The details of these
studies and the results are summarized in Table 2d. In a
cohort study of 49 individuals with overweight, no relation-
ship was observed for Akkermansia muciniphila (A.
muciniphila) with LPS levels (24). A very small Spanish
study of 10 individuals found LPS concentrations to be
negatively correlated with the genera Prevotella and
Bifidobacterium (23). Another Mexican study of 60 individ-
uals, analysed the gut microbiota by qPCR and found that
lower levels of the species E. coli correlated with lower
levels of LPS; however, a positive correlation between LPS
and E. coli was only found in the second tertile (LPS = 1–
1.3 EU/mL) presenting fewer E. coli compared with the first
(LPS < 1 EU/mL) and third (LPS >1.3 EU/mL) tertiles (36).
Discussion
Given the increased prevalence of obesity worldwide, the in-
cidence of ACVD is concomitantly on the rise. Because
ACVD events can only be partly explained by traditional
cardiovascular risk factors, the gut microbiota is a new area
to explore for new diagnostic and therapeutic tools in
ACVD. It has already been shown that the gut microbiome
contributes to a substantial proportion of the variation in
blood lipids (37). Because chronic low-grade inflammation
is one of the hallmarks of obesity, this provides another
route for the gut microbiota to influence the atherosclerotic
process. To our knowledge, this is the first systematic review
of human studies investigating relationships between the gut
microbiota and markers of chronic low-grade inflamma-
tion. Several associations between the gut microbiota and
different markers of chronic low-grade inflammation were
identified. A low gut microbial diversity has previously been
reported in individuals with obesity compared with lean in-
dividuals. However, not just the diversity in gut microbiota,
but also the presence of specific species has been shown to
correlate with chronic low-grade inflammatory markers.
Association of gut microbiome with inflammation
A lower alpha diversity and gene count of the gut
microbiome correlated with higher white blood cell counts
and hsCRP levels. Le Chatelier et al. reported that the met-
abolic phenotype of subjects with an LGC correlated with
increased insulin resistance, higher levels of triglycerides
and free fatty acids, decreased high density lipoprotein-
cholesterol, as well as a marked inflammatory phenotype
compared with individuals with high gene count of the gut
microbiome. These and other data suggest that individuals
with an LGC suffer from metabolic disturbances leading
to an increased risk of diabetes mellitus, dyslipoproteinemia
and pro-inflammatory status which might ultimately lead to
ACVD (24,38,39).
The abundance of the genus Bifidobacterium was in-
versely related to levels of LPS and hsCRP. Bifidobacterium
belongs to the Actinobacteria phyla, whose abundance is re-
lated to a healthier diet with an increased intake of whole
grain cereals and certain vegetables (e.g. black-eyed peas)
(40). Several Bifidobacterium taxa are used as probiotics,
of which a recent meta-analysis revealed protective effects
for cellular immune function (41). Bifidobacterium species
are associated with gut barrier functions, a reduction in
systemic inflammation and a reduction in the incidence of
diabetes in mice (42).
The abundance of the genus Faecalibacterium and species
F. prausnitzii were inversely correlated with hsCRP and
IL-17. Besides showing negative correlations with inflam-
matory markers in individuals with obesity, the proportions
Table 2 (Continued)
Table 2a Gut microbiome measurements in relation to white blood cell counts
Furet JP et al. (32) The strongest associations were found for the amount of F. prausnitzii, which was negatively correlated with serum
concentrations of inflammatory circulating markers, IL-6 (Rs 0.65, P < 0.001)
Table 2d Gut microbiome measurements in relation to LPS
Study Summary of finding
Dao MC et al. (24) No difference in LPS between high and low Akkermansia group
Radilla-Vázquez RB
et al. (36)
A low number of E. coli comes along with a greater risk of having high LPS levels (OR = 4.378, P = 0.005). However, a positive
correlation between LPS and E. coli was only found in the second tertile (LPS = 1–1.3EU/mL) presenting fewer bacteria
compared with the first (LPS < 1EU/mL) and third (LPS > 1.3 EU/mL) tertiles (P = 0.036).
Clemente-Postigo M
et al. (23)
LPS concentrations correlated negatively with P. intermedia (r = 0.336, P = 0.037) and with the genus Bifidobacterium (r =
0.411; P = 0.009).
Impact of gut microbiota on low-grade inflammation I. C. L. van den Munckhof et al. 1725obesity reviews
© 2018 The Authors. Obesity Reviews published by John Wiley & Sons Ltd
on behalf of World Obesity Federation
Obesity Reviews 19, 1719–1734, December 2018
of F. prausnitzii were lower in patients with a history of
stroke, in which the proportion also related with disease
severity (43). Faecalibacterium is regarded as a next-
generation probiotic for its several health-promoting and
anti-inflammatory properties (44).
In general, lower levels of Ruminococcaceae and
Ruminococcus are associated with higher levels of hsCRP
and IL-6. However, opposite correlations have been ob-
served, too; the genus Ruminococcus was highly positively
correlated with both plasma TMA and TMAO levels, as
well as atherosclerotic lesion area in female ApoE/ mice
(45). Another large study seems to confirm this relation as
they found that the abundance of Ruminococcus gnavus
(R. gnavus) was higher in ACVD patients compared with
controls (46). However, it is important to mention that R.
gnavus species were reassigned to the genus Blautia in
2008 on the basis of 16S rRNA gene sequencing and there-
fore belong to the family Lachnospiraceae (47).
The abundance of Prevotellawas inversely associated with
LPS and hsCRP. Furthermore, individuals with obesity have
a lower abundance of Prevotella species in their gut (48).
However, large differences have been observed within this
genus. Human studies have linked the increased abundance
of Prevotella species at mucosal sites to localized and sys-
temic disease, including rheumatoid arthritis, metabolic dis-
orders, as well as low-grade systemic inflammation (49).
Prevotella mediates the inflammatory response via toll-like
receptor (TLR)2 activation andTh17 immune response. This
Prevotella-mediated mucosal inflammation can lead to sys-
temic inflammation. Certain Prevotella species are also sug-
gested to play an important role in the pathophysiological
relation between periodontitis and ACVD. Patients with
ACVDhave an enhanced abundance of Prevotella nigrescens
(P. nigrescens) in subgingival plaques (50).
Gut microbiota in cardiovascular disease
The number of studies performed in humans to investigate
the direct role of the gutmicrobiota inACVD is relatively lim-
ited. Recently, the largest study in patients with ACVD was
conducted by performing a metagenome-wide association
study on stools from 218 individuals with ACVD and 187
healthy controls (46). The abundance of E. coli, Klebsiella
spp, Enterobacter aerogenes, R. gnavus, Eggerthella lenta,
Streptococcus spp, L. salivarius, Solobacterium moorei and
Atopobium parvulumwere elevated in patients with ACVD.
In contrast,Roseburia intestinalis, F. prausnitzii, Bacteroides
spp, P. copri and Alistipes shahii were relatively depleted in
individuals with ACVD. Only smaller cohort studies and
studies with methodological limitations have been published
previously. In 2015, a study was published in which patients
with large-artery atherosclerotic ischemic stroke and tran-
sient ischemic accident patients (n = 141) showed increased
levels of Proteobacteria and reduced amounts ofBacteroides,
Prevotella and Faecalibacterium compared with 94 non-
matched controls by 16S rRNA gene analyses (43). In an-
other small cohort study, the genus Collinsella was found to
be enriched, while the genera Roseburia and Eubacterium
were depleted in 12 symptomatic atherosclerosis patients
compared with 13 controls (51). The apparently beneficial
effects of Bacteroides, Faecalibacterium, Roseburia
(intestinalis) andAlistipes spp have also been found in our re-
view, as they relate to lower levels of inflammatory markers.
Next to this, higher levels of E. coli, Klebsiella spp and
Eggerthella lenta associated with higher levels of inflamma-
tory markers.
Quality and limitations of included studies
Gut microbiome in relation to white blood cell count
Several studies showed a possible association of the gut
microbiome with blood cell counts. The first study by
Mikelsaar et al. had a number of limitations (28), in partic-
ular, focusing only on specific strains of Lactobacillus spe-
cies. The associations could furthermore have been
influenced by the inclusion of subjects with osteoarthritis
and the lack of adjustment in the analysis for smoking sta-
tus. Also, a large number of individuals were taking
probiotics, which may have influenced the microbiota com-
position. The study by Schirmer et al. included only healthy
and mainly young individuals of which the cytokine re-
sponses to different stimuli may not be influenced by
meta-inflammation (27). The association of gut microbiome
with cell counts was also addressed in a large cross-sectional
study by our research group (52), where eight different
blood cell types were measured and related to microbiome
composition, diversity and pathways. However, as we also
included a small number of individuals with inflammatory
bowel disease, this study was not included in our systemic
review. This study identified 17 bacterial species that related
to four different blood cell types and IL-6 levels. A limited
number of species/genera were also found in the current re-
view to be related to markers of chronic low-grade inflam-
mation. For example, Eubacterium ventriosum correlated
negatively to the number of leukocytes and granulocytes,
while R. torques correlated positively to the number of lym-
phocytes. We summarized the relationship between bacte-
rial species, blood cell counts, as well as IL-6 as discussed
in this study in Table S5. After correcting for diet, medica-
tion, various physiological and biomedical measures, self-
reported diseases and smoking status (in total > 200 intrin-
sic and environmental factors), no significant association of
cell counts was observed with bacteria and pathways. This
observation may reflect that the reported cell counts are
not dependent on the gut microbiota; however, it is also
likely that taking into account all available phenotypes to
the analysis model leads to overcorrection, and therefore
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missing the true-positive results or the association is too
small to be detected within the given sample size.
Gut microbiome in relation to (hs)CRP
To measure low levels of hsCRP, a high sensitivity analysis
needs to be used; however, not all studies adopted this
method (30,34). The number of individuals used in the anal-
ysis also varied from 12 to 292. The largest study by Le
Chatelier et al. (26) also used the most robust method to an-
alyse the gut microbiome, quantitative metagenomics. This
contrasts the study by Rajkumar et al. that cultured and
enumerated only six different species (33), or the study by
Brignardello et al. who used G + C peak content analysis
and was unable to find a direct relation between specific
gut microbial species and CRP levels (34).
Gut microbiome in relation to cytokines
In addition to the large differences in gut microbiome com-
position, differences in the cytokine measurements exist.
The study by Schirmer et al. investigated cytokine responses
ex vivo in PBMCs and whole blood stimulations with five
different microbial pathogens (27), while the other studies
measured circulating cytokines in blood.
Gut microbiome in relation to lipopolysaccharide
A major limitation of all the three studies investigating the
relation to LPS is the small sample size, with a maximum
of 49 participants in the study of Dao et al., reducing the
power to detect significant associations. LPS levels in the
study by Radilla-Vazquez et al. and Clemente-Postigo
et al. were assessed by the limulus amebocyte lysate assays;
however, large differences were observed in the concentra-
tions with a mean level of LPS of 0.16 EU/mL in Spanish co-
hort (with a mean age of 48 and mean body mass index
(BMI) of 28) (23) and a mean LPS level of 1.14 EU/mL in
the normal weight and 1.22 EU/mL in the young Mexican
adults with obesity (36). It should be noted that measuring
circulating LPS is notoriously difficult.
General limitations
After reviewing the literature, we could only include 14
studies that investigated the relationship between gut micro-
biota and markers of chronic low-grade inflammation in
humans. Because the techniques used to analyse the gut
microbiome were suboptimal in most studies, several of
these studies could only investigate the gut microbiota at a
specific taxonomic level. However, contradictive associa-
tions can exist in the relationship between different taxon-
omy levels with clinical markers. As already described
before, we found an inverse correlation between the genus
Prevotella and inflammatory markers, while increased
abundance of certain Prevotella species was associated with
low-grade inflammation in systemic diseases, such as rheu-
matoid arthritis (49). This emphasizes the complex
networks among bacterial groups and the large functional
differences between species and strains, which should be
kept in mind when interpreting the results. Larger studies
with state-of-the-art gut microbiome analysis should further
investigate this important association. Another important
limitation is the heterogeneity between study populations.
As mentioned before, the study by Schirmer et al. included
only healthy and mainly young individuals of which the cy-
tokine responses to different stimuli may not be influenced
by meta-inflammation (27). This contrasts investigations
by Claesson et al. where mainly older individuals were in-
cluded (30).
A major limitation in all studies is the cross-sectional de-
sign, which cannot prove causal relationships. Different hu-
man intervention studies have been performed with
probiotics (53) and even faeces transplantation (54).
However, none of these studies investigated the specific ef-
fects of the microbiome species described here in relation
to inflammatory markers. One meta-analysis demonstrated
a protective role for several taxa of Bifidobacterium for cel-
lular immune function in humans (41). Another limitation is
the diversity in the statistical analysis methods. This
depended mainly on the size of the study and the method
of analysis of the microbiome. There is some hierarchy in
the used statistical methods. The larger studies were able
to perform regression analysis adjusting for covariates and
multiple comparisons. Other studies used correlation analy-
sis, either Pearson’s or Spearman’s without corrections. A
number of studies only compared differences between
subgroups of subjects using the Kruskal–Wallis, ANOVA
or Mann–Whitney U test. In Table 1, we give an overview
of the applied statistical methods.
Potential underlying mechanisms
Potential underlying mechanisms are summarized in Fig. 2
Our review focused on human studies, as humans and mice
differ significantly in their gut microbiome composition and
the pathophysiology of cardiovascular disease. Therefore, it
remains to be determined in the future whether data gath-
ered in mice can be directly extrapolated to humans. How-
ever, the human studies are mainly observational and
therefore provide limited insight in the underlying mecha-
nisms. Because the majority of mechanistic studies are per-
formed using animal models, we included these data in
this part of the discussion on potential underlying mecha-
nisms (Table 3).
Pathogen-associated molecular patterns
A possible mechanism for the pro-inflammatory cytokines is
the appearance of pathogen-associated molecular patterns
(PAMPs) derived from microbiota in the gut and the circula-
tion. Such PAMPS can be sensed by PRR. After activating a
PRR, the inflammasome, an important part of our innate
Impact of gut microbiota on low-grade inflammation I. C. L. van den Munckhof et al. 1727obesity reviews
© 2018 The Authors. Obesity Reviews published by John Wiley & Sons Ltd
on behalf of World Obesity Federation
Obesity Reviews 19, 1719–1734, December 2018
Figure 2 Summary of possible gut microbiota derived mechanisms able to influence the process of chronic low-grade inflammation in ACVD. PAMPs, like
peptidoglycans and LPS can stimulate NOD2 or TLR4, respectively, and stimulate the production of pro-inflammatory cytokines via NFκB activation as part
of the inflammasome. SCFAs can stimulate colonocyte proliferation, but also GPR43 and GPR109A activation which leads to the induction of Treg cells and
the production of anti-inflammatory cytokines by Treg and dendritic cells. SCFAs also stimulate the production of gut peptides. GLP-2 production improves
tight junctions and mucosal barrier function. Specific species have an influence on these gut permeability mechanisms. Polyunsaturated fatty acids can
stimulate the CB1 receptor, which promotes gut permeability. Specific species have shown to enhance Treg cell abundance and induce anti-inflammatory
molecules. On the other hand, segmented filamentous bacteria can activate TGF-β and thereby promote the development of Th17 cells. Primary and sec-
ondary bile acids can inhibit NFkB-dependent transcription of pro-inflammatory cytokines from macrophages and dendritic cells via the TGR5 receptor
(55). Taurine increases the production of anti-inflammatory cytokines via NLRP6 inflammasome. TMAO has shown to activate TXNIP-NLRP3 inflammasome
and increase the production of pro-inflammatory cytokines. PAMP pathogen associated molecular pattern; SCFA short chain fatty acid, NOD2 nucleotide-
binding oligomerization domain-containing protein 2; NFκB nuclear factor kappa B; LPS lipopolysaccharide; TLR4 toll-like receptor 4; GPR G protein-
coupled receptor; Treg regulatory T cell; GLP-2R glucagon like protein-2 receptor; GLP-2 glucagon like peptide-2; GHS-R Growth hormone secretagogue
receptor; CB1 cannabinoid receptor 1; TGF-β transforming growth factor beta; TGR5 Takeda G-protein-coupled receptor 5. [Colour figure can be viewed at
wileyonlinelibrary.com]
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immune system that responds to danger signals (56), is acti-
vated with an enhanced production of the transcription fac-
tor nuclear factor kappa B (NF-κB). Different bacterial
components have been demonstrated to be a PAMP and
thereby initiate the inflammasome pathway with NF-κB
production. LPS is believed to confer its deleterious effect
on the cardiovascular system mainly via upregulation of
pro-inflammatory cytokines, a process that is mediated via
TLR4. Importantly, LPS derived from different gut micro-
bial species are not equally toxigenic and can differently in-
duce TLR4 signaling (57). LPS forms a complex with LPS-
binding protein which then binds to CD14 (mainly from
macrophages, but also neutrophils, monocytes and hepato-
cytes) or nucleotide-binding oligomerization domain
(NOD)1, to initiate an acute immune response mainly via
TLRs and NF-κB (58). Humans with obesity exhibit ele-
vated levels of LPS-binding protein (59), possibly contribut-
ing to the explanation of increased LPS levels in these
individuals. Endotoxins derived from gut bacteria are nor-
mally detoxified in the liver. However, when the influx in-
creases, it may exceed the capacity of Kupffer cells and
thereby enter the systemic circulation (60). The importance
of LPS in ACVD has been demonstrated for the first time
by the Bruneck study (61). Subjects with levels exceeding
50 pg mL1 faced a threefold higher risk of developing
incident atherosclerosis. Subclinical endotoxemia was
shown in mice to accelerate atherosclerosis by programming
monocytes into a non-resolving inflammatory state (62).
High fat diet (HFD)-fed mice treated with antibiotics
showed an increase in Prevotella species and a decrease in
endotoxemia (63). This observation is in accordance with
the findings by Clemente et al. and Claesson et al., which
describe an inverse relationship between Prevotella species,
LPS and IL-6 levels (23,30). However, no causal relation-
ships has been shown between the abundance of Prevotella
species and levels of inflammatory markers. Another impor-
tant PAMP is the peptidoglycan that can activate the NOD
receptors. NOD receptors can recognize bacterial determi-
nants once they are phagocytosed by macrophages or den-
dritic cells. HFD-fed mice deficient in NOD2 show
increased bacterial translocation and insulin resistance
(64). A role for NOD2 in atherosclerosis has also been
demonstrated in human genetic and mouse knockout stud-
ies (65,66).
Short chain fatty acids (SCFAs)
Short chain fatty acids are produced by the microbiome
through degradation of dietary fibres; the most important
SCFAs are butyrate, acetate and propionate (67). An impor-
tant function of these SCFA is to promote colonocyte prolif-
eration, which can improve insulin resistance in mice via
promotion of energy expenditure and induction of mito-
chondria function (68,69). SCFAs are also important in
the regulation of appetite via gut hormones (67). Activation
of different G protein coupled receptors (GPR), mainly
GPR41 and GPR43, has been shown to suppress inflamma-
tion, partly via epithelial survival and integrity, but also via
induction of regulatory T (Treg) cells. Activation of
GPR109A by butyrate has been shown to affect colonic
macrophages and dendritic cell maturation and function,
which stimulates the induction of transforming growth fac-
tor (TGF)-β to promote the induction of Treg cells and IL-
10 producing T cells (70). Besides this, butyrate and acetate
act as histone deacetylase inhibitors in dendritic cells and T
cells with modulation of gene expression and contributing
to epigenetic modulation (71). This induces extrathymic
generation of Treg cells from naïve T cells and limits the se-
cretion of pro-inflammatory cytokines (72). F. prausnitzii,
Eubacterium rectale, Eubacterium hallii and R. bromii ap-
pear to be responsible for the majority of butyrate produc-
tion (73); this makes sense given the inverse correlation of
these species with hsCRP and some pro-inflammatory cyto-
kines (27,30–32,35).
Gut peptides
Different gut hormones have been shown to support epithe-
lial barrier formation and anti-inflammatory properties.
Ghrelin levels are decreased in response to HFD and can
promote lymphocyte development in the primary lymphoid
organs (74). Cani et al. reported that higher endogenous
glucagon-like peptide 2 (GLP-2) production is associated
with an improvement of the mucosal barrier function,
improved tight junctions, as well as decreased plasma LPS
concentrations. This was associated with an increased
Table 3 Summary of findings and possible mechanisms
Inflammatory marker Possible mechanism
LPS WBC hsCRP Cytokines
Bacterial diversity and taxonomy IL-6 IL-8 IL-17
↓ Alpha diversity or gene count ↑ ↑ Reduced access to complex carbohydrates
with less production of SCFA
↓ genus Bifidobacterium ↑ ↑ Gut barrier protection
↓ genus Faecalibacterium (and species
F. prausnitzii)
↑ ↑ Production SCFA
↓ genus Ruminococcus (and family Ruminococcaceae) ↑ ↑ Production SCFA
↓ genus Prevotella ↑ ↑ PAMPs
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abundance of Bifidobacterium species (75) and might be
one of the reasons for the inverse observation between
Bifidobacterium species and inflammatory markers
(23,33). Obesity can also enhance the secretion of the pro-
inflammatory serotonin. Indigenous spore-forming bacte-
ria, mainly Clostridium species, can promote serotonin pro-
duction from colonic enterochromaffin cells (76). In mouse
models, it was shown that serotonin could recruit T cells
and stimulate the production of pro-inflammatory cyto-
kines (77,78).
Gut permeability and endocannabinoid system
High fat diet negatively influences gut barrier function by
inducing a number of changes in the gut microbiome and
the endocannabinoid (eCB) system. The eCBs are deriva-
tives of polyunsaturated fatty acids that can activate the
G-coupled receptors CB1 and CB2. When the CB1-receptor
is activated, an increase in the intestinal epithelial barrier
permeability is induced, which can contribute to circulating
LPS concentrations. HFD increases the expression of the co-
lonic CB1 receptor of the eCB system (79). Treatment with
prebiotics leading to a change in gut microbiome was asso-
ciated with a reduction in metabolic endotoxemia and im-
provement of gut barrier function via reduction of the
CB1 receptor (80). Activation of CB2 receptor has been
shown to improve glucose tolerance in rats (81). CB2 recep-
tor expression can mainly be increased by Lactobacillus
supplement, specifically L. acidophilus and decreased by
Clostridium supplement (81,82). Administration of A.
muciniphila in mice increased the levels of eCBs in the small
intestine, which via activation of the CB2 receptor contrib-
ute to the anti-inflammatory effects and improved gut bar-
rier function (83). Besides its effects on gut permeability,
the eCB system has also been shown to control food intake
and energy expenditure both centrally and peripherally
(84). Furthermore, the microbiome can influence gut barrier
function and inflammation directly via specific species like
Bifidobacterium species as well as via the production of
SCFA (75,85,86). However, it should be noted that even if
relations exist between the composition of the gut microbi-
ota and gut permeability, the direct involvement of specific
gut microbes and/or metabolites needs further elucidation.
Bile acids
The gut microbiota can also influence the inflammatory
state of the host through an extensive involvement in bile
acid homeostasis (87). Primary bile acids are derived from
the oxidation of cholesterol in the liver and are secreted into
the intestine to solubilize lipids for absorption. Microbial
bile salt hydrolase, mainly produced by gut bacteria from
the genera Lactobacillus, Bifidobacterium, Clostridium
and Bacteroides, can deconjugate primary bile acids to sec-
ondary bile acids (87). Free taurine, an amino acid to conju-
gate bile acids, can enhance the activation of the NOD-like
receptor family pyrin domain containing 6 (NLRP6)
inflammasome and thereby increase production of IL-18
by the intestinal epithelium, which supports epithelial bar-
rier function (88). Primary and secondary bile acids can in-
hibit NF-κB-dependent transcription of pro-inflammatory
cytokines from monocytes, macrophages, dendritic cells
and kupffer cells via the farnesoid X and Takeda G-pro-
tein-coupled receptor (TGR)5 receptor (55).
Development/differentiation of innate immune cells
An important role for the gut microbiome exists in the
development/differentiation of immune cells. In germ-free
mice fed a diet with low LPS content, the mesenteric lymph
nodes and Peyer’s patches contained fewer CD4+ T lympho-
cytes, mainly due to fewer amounts of CD4+ FoxP3+ Treg
lymphocytes (89). Species belonging to the Clostridium
cluster IV can enhance Treg cell abundance and induce
anti-inflammatory molecules (90). This is in accordance
with the seemingly protective role of Faecalibacterium and
Ruminococcus species (30,31). Furthermore, intestinal
Th17 cell development is dependent on the microbiome.
Dendritic cells and macrophages in the lamina propria sense
segmented filamentous bacteria, such as Clostridia related
bacteria, and produce IL-6 and integrin molecules that con-
tribute to the activation of TGF-β and thereby promote
Th17 cell development in the intestine (91,92). It has been
shown that jejunal T cell inflammation in human obesity
correlates with decreased enterocyte insulin signaling (93).
High fat feeding has also been shown to influence the im-
mune cell populations in the digestive tract. In mice, after
12 weeks of HFD, the proportion of Th1 cells and CD8+
T cells increased in the small bowel and colon, while the
proportion of Treg cells decreased (94).
Trimethylamine-N-oxide (TMAO)
The most convincing link between the gut microbiota and
ACVD is trimethylamine-N-oxide (TMAO) (95), a metabo-
lite derived from dietary choline or carnitine through the ac-
tion of gut bacteria. Bacteria from the phylum
Proteobacteria and Firmicutes (96). TMA is converted in
the liver to TMAO via flavin monooxygenase 3 (FMO3)
(97). TMAO has shown to promote recruitment of acti-
vated leukocytes to human endothelial cells (98). This was
supported by another in vitro study in which TMAO acti-
vated TXNIP-NLRP3 inflammasome and IL-1β and IL-18
were released in a dose- and time-dependent manner, while
endothelial nitric oxide synthase (eNOS) and production of
nitric oxide (NO) were inhibited (99). The same research
group later found that TMAO up-regulated vascular cell ad-
hesion molecule-1 (VCAM-1) expression and promoted
monocyte adherence (100). LDLR-deficient mice fed a cho-
line diet showed elevated inflammatory gene expression
compared with controls (98). ApoE-deficient mice treated
with antibiotics had lower TMAO levels and a reduced
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atheroma size, while supplementing the diet with 1% cho-
line increased foam cell formation, which could be
prevented by antibiotics (101). Faecal transplantation from
high TMAO-producing mice to ApoE-deficient mice accel-
erates atherosclerosis (102). Plasma TMAO levels are an in-
dependent prognostic marker for ACVD in patients
undergoing elective coronary angiography (95).
As discussed above, the gut microbiome can influence
low-grade inflammation via several mechanisms. Because
low-grade inflammation is a hallmark of obesity that is
linked to ACVD, the gut microbiota composition could in-
fluence the risk for atherosclerosis and harbour possible di-
agnostic and therapeutic options. One human study
demonstrated a positive result for faecal transplantation
with regard to obesity-induced insulin resistance (54). Eigh-
teen insulin resistant men who were randomized to duode-
nal infusion of microbiota from either a heterologous lean
donor or an autologous faecal microbiota showed improve-
ment in insulin sensitivity 6 weeks after infusion of microbi-
ota from lean donors. The improvement in insulin
sensitivity in recipient patients correlated with an increase
in the number of butyrate-producing bacteria, pointing to-
wards a regulatory role for butyrate derived from gut micro-
bial metabolism leading to improved insulin sensitivity.
Multiple studies are currently being undertaken to investi-
gate the possibilities of faecal transplantation as treatment
option for obesity and obesity-related complications. Indi-
rect evidence for the influence of the gut microbiota on
ACVD comes from animal studies. ApoE-deficient mice
reared under germ-free conditions fed a low cholesterol diet
exhibited atherosclerotic plaques in the aorta, in contrast to
conventionally reared ApoE-deficient mice fed a low choles-
terol diet who did not develop atherosclerotic aortic plaques
(103). Germ-free mice receiving a faecal transfer from genet-
ically or diet-induced obesity mice with obesity developed
greater adiposity on an HFD than did recipients of microbi-
ota from lean mice (18,104,105). Similarly, faecal transfer
from humans into germ-free mice mirrored the adiposity
of its donor (106). Not only the adiposity status, but also
its complications, like insulin resistance and non-alcoholic
fatty liver disease, were demonstrated to be transmissible
via the gut microbiota (104,107). This has been shown to
be driven (at least partly) by pro-inflammatory microbial
products (63,108).
Perspective
While the gut microbiota is increasingly recognized as a de-
terminant of obesity, its influence on the development of
low-grade inflammation and ACVD remains largely unex-
plored. Future studies should investigate the underlying
pathophysiology, with a focus on mechanisms leading to
low-grade inflammation. This is especially important be-
cause the CANTOS trial has already shown that inhibiting
a pro-inflammatory pathway reduced ACVD related mor-
tality (10). The gut microbiota could serve as a diagnostic
marker by which a more pro-inflammatory state could be
detected in an early stage and could predict the risk to de-
velop certain ACVD states. For these diagnostic options,
first the gut microbiota leading to low-grade inflammation
in humans needs to be established in more detail. Well-
designed clinical studies with state-of-the-art analysis of
the gut microbiota, like shot gun metagenomics, are re-
quired. By using metagenomics analysis, not only the taxon-
omy of the gut microbiota, but also the functionality can be
investigated and can possibly contribute to new diagnostic
strategies. Future studies should include subjects at risk for
ACVD, such as individuals affected by obesity. Future stud-
ies should also focus on prospective and intervention stud-
ies. Potentially, the use of prebiotics or probiotic strains or
faecal microbiota transplantation via capsules could be-
come a promising therapeutic option to prevent low-grade
inflammation and ACVD in the future.
Conclusion
In this review, we have provided an overview of the relation-
ships between the gut microbiota and markers of low-grade
inflammation in humans and discussed the possible mecha-
nisms. These data reinforce the importance of human re-
search into the gut microbiota in relation to the innate and
adaptive immune system to prevent and treat ACVD.
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